The rapid progression of multiple myeloma is dependent upon cellular interactions within the bone marrow microenvironment. In vitro studies suggest that bone marrow stromal cells (BMSCs) can promote myeloma growth and survival and osteolytic bone disease. However, it is not possible to recreate all cellular aspects of the bone marrow microenvironment in an in vitro system, and the contributions of BMSCs to myeloma pathogenesis in an intact, immune competent, in vivo system are unknown. To investigate this, we utilized a murine myeloma model that replicates many features of the human disease. Co-inoculation of myeloma cells and a BMSC line isolated from myeloma-permissive mice in otherwise non-permissive mice resulted in myeloma development, associated with tumor growth within bone marrow and osteolytic bone disease. In contrast, inoculation of myeloma cells alone did not result in myeloma.
INTRODUCTION
The bone marrow is well known to support tumor growth and osteolytic bone disease in multiple myeloma. However, the contributions of this specialized microenvironment during early stages of myeloma development are poorly understood, largely because of the need for in vivo experiments that accurately replicate the complexity of tumor-host cell interactions. To address this, we have exploited the unique opportunities provided by the well-characterized 5T Radl myeloma model, where transplantation of 5T myeloma cells into recipient mice of the specific C57Bl/KaLwRijHsd (KaLwRij) substrain results in propagation of myeloma with many features of the human disease (1) . One important feature of the Radl model is that 5T myeloma cells will only grow in syngeneic KaLwRij mice, and not in closely-related C57Bl6 mice. Since there is an emerging role for host fibroblasts in the establishment and progression of solid tumors (2) (3) (4) , we hypothesized that fibroblasts, or bone marrow stromal cells (BMSCs), from myelomapermissive KaLwRij mice may promote myeloma development in environments that are otherwise not permissive for myeloma. Furthermore, increasing evidence for elevated Dickkopf 1 (Dkk1) in patients with monoclonal gammopathy of undetermined significance (MGUS) (5) (6) (7) suggests a potential role for host-derived Dkk1 in the early stages of myeloma. We utilized a BMSC line derived from KaLwRij mice to determine the function of BMSCs and BMSC-derived Dkk1 in myeloma pathogenesis in vivo.
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MATERIALS AND METHODS

Cell Culture
5TGM1-GFP myeloma cells were cultured as previously described (8) . 14M1 BMSCs were originally isolated from KaLwRij mice bearing 5T myeloma. Bone marrow was flushed from long bones, and cells cultured in DMEM media with 10% fetal calf serum and L-glutamine. Media was changed every 3-4 days, and adherent cells were maintained in culture. The cell line was generated by continuous growth in vitro, with no requirement for cellular or viral immortalizing genes. Aliquots of early passage cells were frozen in 10% DMSO/90% FCS and stored in liquid nitrogen. ST2 BMSCs were purchased from Riken cell Bank, (Tsukuba, Japan) and maintained in DMEM media with 10% fetal calf serum and L-glutamine.
Stable Cell Lines
14M1 BMSCs were transfected with 1ug Dkk1shRNA or scrambled control (Santa Cruz Biotechnology, Santa Cruz, CA) using shRNA transfection reagent and standard protocols. Cells were cultured in DMEM with 10ug/ml puromycin. Knockdown of Dkk1 expression was confirmed by ELISA and cells were continuously cultured in puromycin to maintain knockdown. ST2 BMSCs were transfected with 250ng full-length Dkk1 cDNA (OriGene, Rockville, MD) or empty vector control according to the manufacturer's instructions. Cells were cultured in DMEM with 800ug/ml neomycin. Over-expression of Dkk1 was confirmed by ELISA and cells were continuously cultured in neomycin to maintain expression. 
Differentiation Studies
BMSCs were cultured in either control media, osteoblast differentiation media (10mM β-glycerophosphate, 50ug/ml ascorbic acid, 10ng/ml BMP-2) or adipocyte differentiation media (10nM dexamethasone, 5ug/ml insulin) for 7 days (osteoblast differentiation) or 10 days (adipocyte differentiation). Osteoblasts were identified by alkaline phosphatase staining, using a BCIP/NBT substrate kit and adipocytes by Oil Red-O staining.
ELISA, Western blotting and flow cytometry
The concentration of Dkk1 in conditioned media or sera was measured by ELISA, according to the manufacturers instructions (R & D Systems). Sera were assayed for monoclonal mouse IgG 2bκ paraprotein as described (8) . Western blotting and flow cytometry were performed as previously described, and outlined in Supplemental Data (9) .
In vivo studies.
Studies were conducted using weight-matched, 8 
Histology, microCT and histomorphometric analyses
Histomorphometric analysis was performed to quantify bone volume and osteoclast and osteoblast surface area to bone surface area. Tibias and femurs were formalin-fixed, decalcified in 14% EDTA, paraffin-embedded, sectioned along the mid-sagittal plane in 4uM thick sections and stained with hematoxylin and eosin. To visualize osteoclasts, sections were stained for TRAP activity. For visualization of tetracycline labeling, spines were fixed in 70% ethanol and embedded in methylmethacrylate without prior decalcification. 6uM sections were cut and viewed unstained by epifluorescecen microscopy. Three non-consecutive sections were evaluated using Osteomeasure histomorphometry software, as described previously (9) . Tibias were fixed in formalin and each bone was scanned at an isotropic voxel size of 12um using a microCT40 (SCANCO Medical, Bassersdorf, Switzerland). Images were analyzed using the Computer Systems, Chelmsford, MA) to quantitate cortical bone lesions and trabecular bone volume, as described previously (9) . Fluorescent in situ hybridization (FISH), immunohistochemistry and immunocytochemistry were performed as detailed in Supplemental Methods.
Statistical Analysis
Statistical significance was determined using a Mann-Whitney U test for nonparametric data, or one-way ANOVA followed by Tukey's post-hoc test. Data was considered significant given p≤0.05. Data are presented as means (± SEM) unless otherwise stated. 
RESULTS AND DISCUSSION
The importance of the host microenvironment in myeloma is exemplified by the 5T myeloma model, in which KaLwRij mice possess a unique host microenvironment that is permissive for 5T myeloma growth (10) We were able to induce myeloma development Figure 1D ). Inoculation of 5TGM1 myeloma cells alone into C57Bl6 mice did not result in the development of myeloma, with no significant accumulation of plasma cells within the bone marrow or evidence of osteolytic bone disease. There is increasing evidence from solid tumors to support a role for fibroblasts in tumor progression (11, 12) . In contrast to previously published studies, where the fibroblasts were enhancing tumor growth, we have identified a role Author Manuscript Published OnlineFirst on February 28, 2012; DOI: 10.1158/0008-5472. CAN-11-2067 but no change in osteoclast number ( Figure 3A-3B) . In control experiments, inoculation of ST2 BMSCs was found to have no effect on trabecular bone volume, bone cell number or bone formation rates (data not shown). In support of a decrease in trabecular bone volume contributing to myeloma development, KaLwRij mice were also found to have a significant reduction in trabecular bone volume (Supplementary Figure 5 ) when compared to age-and sex-matched C57Bl6 mice.
Since a major mediator of osteoblast suppression in myeloma bone disease is Dkk1 (13- Figure 7) . Therefore, we determined the contribution of BMSC-derived Dkk1 in myeloma pathogenesis in vivo. 14M1 BMSCs were stably transfected with Dkk1 shRNA or scrambled control, and knockdown of Dkk1 expression was confirmed by ELISA ( Figure   4A ). Knockdown of Dkk1 expression had no effect on the growth rate of 14M1 BMSCs in vitro (data not shown). C57Bl6 mice were inoculated with 5TGM1 myeloma cells in Dkk1 plays a key role in the osteoblast suppression of myeloma bone disease, but the majority of studies to date have focused upon the role of myeloma-derived Dkk1 (13, 14) . Stromal cells and osteoblasts are known sources of Dkk1 (16, 17) , and the present study provides compelling evidence for a key role of stromal-derived Dkk1 to promote myeloma development. There is increasing evidence to suggest that cells of the bone marrow microenvironment are altered in MGUS, and that Dkk1 is increased in patients with MGUS, associated with a loss of trabecular bone (5) (6) (7) . In support of this, our studies demonstrate increased host-derived Dkk1 in myeloma-permissive KaLwRij mice that is associated with a significant reduction in trabecular bone volume. Furthermore, we have discovered a novel role of BMSCs to promote myeloma establishment and progression in an otherwise non-permissive environment. This is mediated, in part, -2067 through stromal-derived Dkk1, however the inability of over-expression of Dkk1 in normal BMSCs to support myeloma development reveals that Dkk1 alone is not permissive for myeloma development and suggests a requirement for additional factors.
Furthermore, although Dkk1 expression is undetectable in vitro, 5TGM1 myeloma cells do express Dkk1 in vivo, raising the possibility that tumor-derived Dkk1 may compensate for a loss in host-derived Dkk1 (Supplementary Figure 7) .
It is intriguing to speculate whether the effect of 14M1 BMSCs is associated with a generalized osteoblast suppression that renders the bone marrow microenvironment 
